PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gilteritinib→

Gilteritinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1254053-43-4
Molecular formula
C29H44N8O3
Molecular weight
552.7 g/mol
Drug class
FMS-like tyrosine kinase 3 (FLT3) inhibitortargeted antineoplastic kinase inhibitor
Mechanism of action
Inhibits FLT3 receptor tyrosine kinase signalling, including FLT3-ITD and FLT3-TKD mutations, reducing downstream proliferative signalling in FLT3-mutated leukaemic cells. It also inhibits additional kinases at clinically relevant concentrations.
Indications / reported uses
  • Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation detected by an FDA-approved test; specialist haematology use

Sources: US DailyMed — XOSPATA (gilteritinib) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Gilteritinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gilteritinib Permitted Daily Exposure (PDE) report (the Gilteritinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gilteritinib Occupational Exposure Limit (OEL) report (the Gilteritinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.